Dr. Mascola joined ModeX Therapeutics in April 2022 as its Chief Scientific Officer.  Prior to that, he was the Director of the Vaccine Research Center, NIAID, NIH where he oversaw programs on vaccines and antibody therapeutics for major diseases such as HIV, Ebola, Respiratory Syncytial Virus, Zika and COVID-19. Under his leadership, the VRC established collaborative partnerships leading to the licensure of a therapeutic monoclonal antibody to treat Ebola virus disease and the development and licensure of COVID-19 antibodies and an mRNA vaccine. Dr. Mascola earned a Medical Degree from the Georgetown University School of Medicine and completed a residency in internal medicine and fellowship in infectious diseases.  He has received numerous awards including the outstanding service medal form the U.S. Department of Health and Human services and election to the American Society of Clinical Investigation, the Association of American Physicians and the National Academy of Medicine